• 作者：M. Gonzá ; lez-Forero ; E. Prieto ; I. Domí ; nguez ; C. Vigil ; I. Peñ ; uelas ; J. Arbizu ; ^{jarbizu@unav.es}
• 关键词：18F-FDOPA ; Tomografí ; a por emisió ; n de positrones ; Tumores cerebrales
• 刊名：Revista Espa帽ola de Medicina Nuclear
• 出版年：2011
• 期刊代码：pca315_02126982
• 类别：med
• 出版时间：March-April 2011
• 卷：30
• 期：2
• 页码：88-93
• 文件大小：391 K

¹⁸F-FDOPA is an amino acid analogue used to evaluate presynaptic dopaminergic activity, which has aroused great interest in neuro-oncology. We have evaluated five ¹⁸F-FDOPA PET studies of patients referred for study of parkinsonian syndrome. Two subjects had previously treated high-grade brain tumors, one nonspecific brain injury, and 2 subjects presented unexpected tumoral lesions. For all lesions SUVmax, time to SUVmax and tumor-to-normal grey matter SUVmax rate (T/N) were calculated, and 90 minutes ¹⁸F-FDOPA kinetics were analyzed. Tumor lesions corresponded to three malignant neurocytomas, one meningioma, one pineocytoma and one intrasinusal hemangioma. Both malignant and benign tumors exhibited high uptake of ¹⁸F-FDOPA well above the normal cortex. However, the analysis of the curve uptake displayed characteristic patterns that facilitate the characterization of tumor lesions. A dual phase maximum uptake was observed, with an early 10 minutes uptake in malignant lesions, and a late 60 to 90 minutes uptake in benign or low grade lesions.